Sayfa yüklenirken bir hata oluştu.
Teknik ekibimiz bilgilendirildi, ancak sorunun devam etmesi durumunda lütfen e-posta destek widget ile bize ulaşın.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM EBITDA Multiple | -4,1x - -4,5x | -4,3x |
| Selected Fwd EBITDA Multiple | 3,7x - 4,1x | 3,9x |
| Fair Value | $1,50 - $1,60 | $1,55 |
| Upside | 1,4% - 8,4% | 4,9% |
| Benchmarks | Ticker | Full Ticker |
| bluebird bio, Inc. | BLUE | NasdaqGS:BLUE |
| BioMarin Pharmaceutical Inc. | BMRN | NasdaqGS:BMRN |
| Agios Pharmaceuticals, Inc. | AGIO | NasdaqGS:AGIO |
| Vertex Pharmaceuticals Incorporated | VRTX | NasdaqGS:VRTX |
| BioRestorative Therapies, Inc. | BRTX | NasdaqCM:BRTX |
| Geron Corporation | GERN | NasdaqGS:GERN |
| - | - | - |
| Select LTM EBITDA Multiple | |||||||
| Benchmark Companies | |||||||
| BLUE | BMRN | AGIO | VRTX | BRTX | GERN | ||
| NasdaqGS:BLUE | NasdaqGS:BMRN | NasdaqGS:AGIO | NasdaqGS:VRTX | NasdaqCM:BRTX | NasdaqGS:GERN | ||
| Historical EBITDA Growth | |||||||
| 5Y CAGR | NM- | 332.0% | NM- | 29.5% | NM- | NM- | |
| 3Y CAGR | NM- | 170.4% | NM- | 5.9% | NM- | NM- | |
| Latest Twelve Months | 49.6% | 162.6% | -12.4% | 0.0% | 9.9% | 36.2% | |
| Historical EBITDA Profit Margin | |||||||
| 5 Year Average Margin | -2828.9% | 8.4% | -4842.6% | 47.8% | -16290.0% | -23687.4% | |
| Prior Fiscal Year | -731.4% | 12.0% | -1434.8% | 45.4% | -10325.8% | -81646.4% | |
| Latest Fiscal Year | -246.3% | 23.4% | -1151.0% | 43.3% | -2834.4% | -224.9% | |
| Latest Twelve Months | -143.5% | 27.3% | -1173.8% | 41.3% | -3083.2% | -115.0% | |
| Current Trading Multiples | |||||||
| EV / LTM Revenue | 1.80x | 3.36x | 13.13x | 9.35x | 9.55x | 5.45x | |
| EV / LTM EBITDA | -1.3x | 12.3x | -1.1x | 22.6x | -0.3x | -4.7x | |
| EV / LTM EBIT | -0.9x | 13.9x | -1.1x | 23.5x | -0.3x | -4.7x | |
| Low | Mid | High | |||||
| Benchmark EV / LTM EBITDA | -1.3x | -0.3x | 22.6x | ||||
| Historical EV / LTM EBITDA | -8.9x | -4.4x | -2.0x | ||||
| Selected EV / LTM EBITDA | -4.1x | -4.3x | -4.5x | ||||
| (x) LTM EBITDA | (134) | (134) | (134) | ||||
| (=) Implied Enterprise Value | 544 | 573 | 602 | ||||
| (-) Non-shareholder Claims * | 334 | 334 | 334 | ||||
| (=) Equity Value | 878 | 907 | 935 | ||||
| (/) Shares Outstanding | 636.9 | 636.9 | 636.9 | ||||
| Implied Value Range | 1.38 | 1.42 | 1.47 | ||||
| FX Rate: USD/USD | 1.0 | 1.0 | 1.0 | Market Price | |||
| Implied Value Range (Trading Cur) | 1.38 | 1.42 | 1.47 | 1.48 | |||
| Upside / (Downside) | -6.8% | -3.8% | -0.8% | ||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | BLUE | BMRN | AGIO | VRTX | BRTX | GERN | |
| Enterprise Value | 187 | 10,051 | 472 | 105,038 | 4 | 609 | |
| (+) Cash & Short Term Investments | 79 | 1,272 | 893 | 6,201 | 9 | 397 | |
| (+) Investments & Other | 0 | 507 | 531 | 5,221 | 0 | 59 | |
| (-) Debt | (217) | (602) | (53) | (1,649) | 0 | (122) | |
| (-) Other Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Preferred Stock | 0 | 0 | 0 | 0 | (0) | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 49 | 11,228 | 1,844 | 114,811 | 13 | 943 | |
| (/) Shares Outstanding | 9.8 | 191.8 | 57.9 | 256.8 | 7.5 | 636.9 | |
| Implied Stock Price | 4.97 | 58.55 | 31.84 | 447.09 | 1.75 | 1.48 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 4.97 | 58.55 | 31.84 | 447.09 | 1.75 | 1.48 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |